Anti-BRG1 Antibody, clone 1N12, ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 1N12 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Transcription activator BRG1. It targets an epitope within 65 amino acids from the N-terminal region.
• Immunogen: His-tagged recombinant fragment corresponding to 65 amino acids from the N-terminal region of human Transcription activator BRG1.
• Application: Anti-BRG1, clone 1N12 ZooMAb, Cat. No. ZRB1148, is a highly specific recombinant rabbit monoclonal antibody that specifically targets Transcription activator BRG1 and has been tested for use in Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.
• Target description: Transcription activator BRG1 (UniProt: P51532; also known as ATP-dependent helicase, SMARCA4, BRG1-associated factor 190A, BAF190A, Mitotic growth and transcription activator, Protein BRG-1, Protein brahma homolog 1, SNF2-beta, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4) is encoded by the SMARCA4 (also known as BAF190A, BRG1, SNF2B, SNF2L4) gene (Gene ID: 6597) in human. BRG1 is a component of the multiprotein chromatin-remodeling complexes SWI/SNF: SWI/SNF-A (BAF), SWI/SNF-B (PBAF) and related complexes. The SWI/SNF complexes contain 10-12 interchangeable subunits, with either BRG1/SMARCA4 or BRM/SMARCA2 as the ATPase subunit. These complexes drive conformational changes of nucleosomes in an ATP-dependent manner and play important roles in cell-cycle progression, DNA repair, and development. BRG1 is shown to maintain Polycomb-mediated repression of non-mesodermal developmental regulators. Studies have shown that BRG1 knockout leads to disruption of murine ESC cardiomyocyte differentiation and dysregulation of lineage-specific gene expression during mesoderm induction. Mutations in SMARCA4/BRG1 gene can cause rhabdoid tumor predisposition syndrome 2 that predisposes subject to renal or extrarenal malignant rhabdoid tumors. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose. Normal appearance is a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.